Edition:
United States

Aptose Biosciences Inc (APTO.OQ)

APTO.OQ on NASDAQ Stock Exchange Capital Market

2.69USD
16 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.69
Open
$2.67
Day's High
$2.76
Day's Low
$2.63
Volume
18,703
Avg. Vol
76,003
52-wk High
$3.87
52-wk Low
$0.78

Chart for

About

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates... (more)

Overall

Beta: 2.56
Market Cap(Mil.): $74.04
Shares Outstanding(Mil.): 27.50
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Aptose Biosciences Inc Files For Stock Shelf Of Upto $100 Mln

* APTOSE BIOSCIENCES INC FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING Source text : http://bit.ly/2BJGvqH Further company coverage:

Feb 07 2018

BRIEF-FDA Grants Orphan Drug Designation To Aptose Biosciences For CG’806 In Acute Myeloid Leukemia

* FDA GRANTS ORPHAN DRUG DESIGNATION TO APTOSE BIOSCIENCES FOR CG’806 IN ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage:

Dec 26 2017

BRIEF-Aptose Biosciences Inc Q3 loss per share C$0.14

* Aptose reports results for the third quarter ended September 30, 2017

Nov 14 2017

BRIEF-Aptose enters into $15.5 mln common shares purchase agreement with Aspire Capital Fund, Llc

* Aptose enters into $15.5 million common shares purchase agreement with Aspire Capital Fund, Llc

Oct 30 2017

Earnings vs. Estimates